As part of our ongoing aim to bring you reports of new developments, we have added a review on U-ACTIVATE which is an ongoing phase 3 study examining the long-term efficacy and safety of upadacitinib (oral, selective JAK inhibitor) in patients with moderately to severely active ulcerative colitis.
Independent commentary for the review has been provided by Associate Professor Emily Wright, a gastroenterologist at St Vincent’s Hospital Melbourne and Head of The Inflammatory Bowel Diseases (IBD) Unit and a principal research (NHMRC) fellow at The University of Melbourne.
Please login below to download this issue (PDF)